Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(13):950-951; doi:10.1093/jnci/dji194
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Success of Bevacizumab Trials Raises Questions for Future Studies

Rabiya S. Tuma

The first 150 words of the full text of this article appear below.

The fortunes of antiangiogenesis therapies have swung between promises of glory and dashed hopes. Now, with several large-scale clinical trials finding that combination regimens that include the drug bevacizumab (Avastin) improve progression-free survival and overall survival in certain cancers, reality seems to have settled somewhere in the middle. It is clear that bevacizumab, the only angiogenesis inhibitor with U.S. Food and Drug Administration approval, seems to be effective in multiple cancers, but just when and how clinicians should use it for optimal results are still up for discussion.

The popularity of and interest in angiogenesis inhibitors soared in 1998 when the New York Times published a front-page story reporting that Judah Folkman, M.D., a professor at Harvard Medical School, and Michael O'Reilly, M.D., now of the University of Texas M. D. Anderson Cancer Center in Houston, and colleagues used the drugs endostatin and angiostatin to successfully treat metastatic disease in . . . [Full Text of this Article]

Combination Therapy

Toxicity

Dosing


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. Knogler, J. Grunberg, K. Zimmermann, S. Cohrs, M. Honer, S. Ametamey, P. Altevogt, M. Fogel, P. A. Schubiger, and I. Novak-Hofer
Copper-67 Radioimmunotherapy and Growth Inhibition by Anti-L1-Cell Adhesion Molecule Monoclonal Antibodies in a Therapy Model of Ovarian Cancer Metastasis
Clin. Cancer Res., January 15, 2007; 13(2): 603 - 611.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J Heidemann, D G Binion, W Domschke, and T Kucharzik
Antiangiogenic therapy in human gastrointestinal malignancies.
Gut, October 1, 2006; 55(10): 1497 - 1511.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu
Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms.
Clin. Cancer Res., August 15, 2006; 12(16): 4794 - 4803.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Sosman and I. Puzanov
Molecular targets in melanoma from angiogenesis to apoptosis.
Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s.
[Abstract] [Full Text] [PDF]